AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) – Wedbush issued their Q1 2023 EPS estimates for AVROBIO in a report released on Tuesday, May 10th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.29) per share for the quarter. Wedbush also issued estimates for AVROBIO’s Q2 2023 earnings at ($0.30) EPS, Q3 2023 earnings at ($0.24) EPS, Q4 2023 earnings at ($0.24) EPS and FY2026 earnings at ($0.43) EPS.
AVROBIO (NASDAQ:AVRO – Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.10).
AVROBIO stock opened at $0.76 on Thursday. The firm’s 50-day moving average is $1.22 and its 200-day moving average is $2.56. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.27 and a current ratio of 10.27. AVROBIO has a 1 year low of $0.76 and a 1 year high of $11.00. The company has a market cap of $33.21 million, a P/E ratio of -0.27 and a beta of 1.73.
Institutional investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd acquired a new position in AVROBIO during the 3rd quarter valued at about $26,000. BNP Paribas Arbitrage SA grew its stake in shares of AVROBIO by 112.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 9,665 shares of the company’s stock worth $54,000 after purchasing an additional 5,117 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of AVROBIO in the 3rd quarter worth approximately $63,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of AVROBIO in the 3rd quarter worth approximately $63,000. Finally, Raymond James & Associates acquired a new position in shares of AVROBIO in the 3rd quarter worth approximately $85,000. 63.92% of the stock is currently owned by hedge funds and other institutional investors.
About AVROBIO (Get Rating)
AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.
- Get a free copy of the StockNews.com research report on AVROBIO (AVRO)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.